Drug combination slows progression of treatment resistant bone marrow cancer

December 12, 2006

CHAPEL HILL -- Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.

The phase III trial included 646 patients from 18 countries with relapsed or refractory multiple myeloma, a condition in which cancerous cells continue to multiply despite treatment. Patients in the trial were randomly assigned to receive the drug bortezomib (Velcade), standard therapy for relapsed multiple myeloma, or a combination of Velcade and Doxil, a chemotherapy drug (doxorubicin) delivered via liposomes, or microscopic fat bubbles.

An interim analysis of study participants who received the combination treatment showed a better response in the combination group than in participants who received standard treatment. The combination group's median time to progression - the time interval between the response to treatment and the time the disease starts to show evidence of growing or recurring - was 9.3 months, while those on Velcade alone progressed after 6.5 months.

The three-month improvement is an important step forward in treatment for multiple myeloma, said Dr. Robert Orlowski, Lenvel Lee Rothrock associate professor in the department of hematology/oncology at the School of Medicine, and a member of the UNC Lineberger Comprehensive Cancer Center.

Orlowski presented the trial's early results on Monday (Dec. 11), at the meeting of the American Society of Hematology in Orlando, Fla. The study was supported by Johnson & Johnson, which owns Ortho Biotech, the maker of Doxil, and also has a financial interest in Velcade.

"The data for time to progression were so positive and encouraging that we decided to announce this information earlier than anticipated so more people could be aware of the benefits of this combination," said Orlowski.

"This study establishes that this combination is one of the standards of care for relapsed, refractory multiple myeloma," Orlowski said. "It does provide some added hope for patients and their families."

The interim analysis also showed an early trend toward increased survival for patients taking the combination treatment, Orlowski said. Additional data on survival and the complete results of this analysis, as well as other factors such as quality of life, will be reported at a later date.

More than 11,000 people in the United States will die of multiple myeloma in 2006, according to the American Cancer Society. Because it affects white blood cells, multiple myeloma suppresses the immune system, so patients can develop sometimes-fatal infections. Other complications include kidney failure, bone pain, anemia, and bleeding.

Doxil is a liposmal version of an older drug, doxorubicin, which means the drug is encapsulated in a microscopic pouch made of lipids, or fats. The formulation seems to produce fewer cardiac side effects and is more convenient to administer.

Orlowski and others first found that doxorubicin and Doxil may complement Velcade in studies of cells in culture, and of mice. "We've been able to take findings from the laboratory and move them on to patients in early, phase I clinical trials, and now in this phase III trial," Orlowski said. "It's an excellent example of how support of basic and translational laboratory research can, in a short time period, result in tangible benefits to patients."
-end-
Other investigators were Sen H. Zhuang, Trilok Parekh and Liang Xiu, all of Johnson and & Johnson Pharmaceutical Research & Development, and Jean-Luc Harousseau of University Hospital Hotel-Dieu, Nantes, France.

Note: School of Medicine contact: Leslie Lang
Lineberger Center contact: Dianne Shaw, (919) 966-7834, dgs@med.unc.edu

University of North Carolina Health Care

Related Multiple Myeloma Articles from Brightsurf:

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine.

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.

Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Read More: Multiple Myeloma News and Multiple Myeloma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.